Georgia CTSA Investigators Encouraged by COVID-19 Vaccine Trial
Georgia CTSA investigators Evan Anderson, MD, and Nadine Rouphael, MD, co-authored results published in NEJM reporting a robust anti-SARS-CoV-2 immune response in all study participants during the investigational mRNA-1273 vaccine phase 1 trial. Anderson is the principal investigator and Rouphael is the contact principal investigator for the trial at Emory. The phase 3 efficacy trial is scheduled to begin on July 23.